Illumina rejects Roche’s $6.7-bn bid

03 Apr 2012

1

US-based gene sequencing company Illumina Inc yesterday rejected Swiss drugmaker Roche Holding's increased takeover offer, saying it dramatically undervalued the company.

Basel, Switzerland-based Roche, the world's biggest maker of cancer drugs, had last week increased its $44.50 a share offer by 15 per cent, to $51 a share, taking Illumina's purchse price to $6.7 billion. (See: Roche increases hostile offer for Illumina to $6.7 billion)

The Illumina board told its shareholders that accepting the revised offer was not in their best interests, and urged them not to tender any shares.

The San Diego, California-based company said in a statement that the revised offer ''dramatically undervalues Illumina and does not adequately reflect Illumina's singular position in an industry poised for extraordinary growth.''

''Illumina has strong revenue generation, strong profit generation, strong cash generation and a very good track record of delivering continual upgrades in technology to the marketplace.''

The rejection will see a proxy battle ahead of Illumina's annual shareholders' meeting scheduled to be held on 18 April, where Roche has proposed that shareholders elect six of its nominees to Illumina's board.

Business History Videos

History of hovercraft Part 3...

Today I shall talk a bit more about the military plans for ...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of hovercraft Part 2...

In this episode of our history of hovercraft, we shall exam...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Hovercraft Part 1...

If you’ve been a James Bond movie fan, you may recall seein...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Trams in India | ...

The video I am presenting to you is based on a script writt...

By Aniket Gupta | Presenter: Sheetal Gaikwad

view more